drugset
drugset / Trial / NCT00160329

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

NCT00160329 ↗

Phase 3 Completed 60 enrolled Stanford University Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is looking to compare the impact of lipid levels and HIV viral loads between three different drug regimens: Continuing current regimen (ritonavir boosted regimen), Switching to Atazanavir, or Switching to Atazanavir in combination to Ritonavir.

Timeline

Start
2004-01
Primary completion
2007-04
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg —
Subject Atazanavir Other / unclassified 400 mg —

Indications

HIV infectious disease hyperlipidemia